HomeCompareOBSV vs MRK

OBSV vs MRK: Dividend Comparison 2026

OBSV yields 1964.64% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OBSV wins by $8418661323.94M in total portfolio value
10 years
OBSV
OBSV
● Live price
1964.64%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8418661324.00M
Annual income
$7,652,437,982,425,691.00
Full OBSV calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — OBSV vs MRK

📍 OBSV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOBSVMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OBSV + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OBSV pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OBSV
Annual income on $10K today (after 15% tax)
$166,994.11/yr
After 10yr DRIP, annual income (after tax)
$6,504,572,285,061,837.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, OBSV beats the other by $6,504,572,285,053,240.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OBSV + MRK for your $10,000?

OBSV: 50%MRK: 50%
100% MRK50/50100% OBSV
Portfolio after 10yr
$4209330662.03M
Annual income
$3,826,218,991,217,902.50/yr
Blended yield
90.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

OBSV
Analyst Ratings
9
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$6.00
+5793.9% upside vs current
Range: $6.00 — $6.00
Altman Z
-39.0
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OBSV buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOBSVMRK
Forward yield1964.64%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$8418661324.00M$57.7K
Annual income after 10y$7,652,437,982,425,691.00$10,113.78
Total dividends collected$8364201739.80M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$6.00$128.54

Year-by-year: OBSV vs MRK ($10,000, DRIP)

YearOBSV PortfolioOBSV Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$207,164$196,463.65$11,213$373.04+$196.0KOBSV
2$4,025,415$3,803,750.33$12,667$512.06+$4.01MOBSV
3$73,382,907$69,075,712.04$14,439$708.14+$73.37MOBSV
4$1,255,382,398$1,176,862,688.09$16,640$988.16+$1255.37MOBSV
5$20,159,078,828$18,815,819,662.20$19,432$1,394.07+$20159.06MOBSV
6$303,950,265,341$282,380,050,994.39$23,057$1,992.90+$303950.24MOBSV
7$4,304,301,356,343$3,979,074,572,429.02$27,889$2,894.79+$4304301.33MOBSV
8$57,267,735,234,320$52,662,132,783,032.35$34,518$4,286.29+$57267735.20MOBSV
9$716,096,580,908,859$654,820,104,208,136.60$43,912$6,494.35+$716096580.86MOBSV
10$8,418,661,323,998,170$7,652,437,982,425,691.00$57,714$10,113.78+$8418661323.94MOBSV

OBSV vs MRK: Complete Analysis 2026

OBSVStock

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

Full OBSV Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this OBSV vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OBSV vs SCHDOBSV vs JEPIOBSV vs OOBSV vs KOOBSV vs MAINOBSV vs JNJOBSV vs ABBVOBSV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.